In vivo characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: A technical note

AAPS PharmSciTech

Volumn 7, Issue 1, 2006, Pages

  Aqil, Mohd ^a   Ali, Asgar ^a   Sultana, Yasmin ^a   Dubey, Kiran ^a   Najmi, Abul K ^a   Pillai, Kollapa K ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Hypertension; Methylprednisolone acetate; Pinacidil; Rat; Transdermal drug delivery system

Indexed keywords

METHYLPREDNISOLONE ACETATE; PINACIDIL; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; METHYLPREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MALE; NONHUMAN; PATIENT COMPLIANCE; RAT; SKIN PERMEABILITY; TABLET; TRANSDERMAL PATCH; ANIMAL; BLOOD PRESSURE; CHEMISTRY; DRUG EFFECT; INTRADERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HYPERTENSION; MALE; METHYLPREDNISOLONE; PINACIDIL; RATS;

EID: 33645744827     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt070106     Document Type: Article

References (24)

1. Ishii R, Tagawa T, Ishida T, Naruse T. Antihypertensive effects of a new TDS of clonidine in genetic and experimental rats. Arzneimittelforschung. 1996;46:261-268. PubMed
2. Corbo M, Liu JC, Chien YW. Transdermal controlled delivery of propranolol from a multilaminate adhesive device. Pharm Res. 1989:6:753-758. PubMed DOI: 10.1023/A:1015967329033
3. Kommuru TR, Khan MA, Reddy TK. Effect of chiral enhancers on the permeability of optically active and racemic metoprolol across hairless mouse skin. Chirality. 1999;11:536-540. PubMed DOI: 10.1002/ (SICI)1520-636X(1999)11:7<536::AID-CHIR4>3.0.CO_2-H
4. Aqil M, Sultana Y, Ali A. Monolithic matrix type transdermal drug delivery systems of metoprolol tartrate: in-vitro characterization. Acta Pharm. 2003;53:119-126. PubMed
5. Spieker C, Vetter H, Liedtke R, Zidek W, Vetter W, Transdermal beta-blocker therapy in essential hypertension. Am J Hypertens. 1988;1:199S-200S. PubMed
6. Shah HS, Tojo K, Chien YW. Transdermal controlled delivery of verapamil: characterization of in vitro skin permeation. Int J Pharm. 1992;86:167-173. DOI: 10.1016/0378-5173(92)90194-7
7. Dubey BK. Lypophilzed aqueous-based polymer matrices for transdermal delivery of captopril. J Dermatol Sci. 1995;10:191-195. PubMed DOI: 10.1016/0923-1811(95)00403-F
8. Rao PR, Diwan PV. Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Ind Pharm. 1998;24:327-336. PubMed
9. Thacharodi D, Rao KP. Transdermal absorption of nifedipine from microemulsions of lipophillic skin penetration enhancers. Int J Pharm. 1994;111:235-240. DOI: 10.1016/0378-5173(94)90346-8
10. Aqil M, Ali A. Effect of penetration enhancers on transdermal delivery of pinacidil monohydrate. J Sci Pharm, 2002;3:68-71.
11. McBurney A, Farrow PR, Ainsworth S, Ward JW. Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following iv and oral administration in healthy volunteers. Br J Clin Pharmacol. 1985;19:91-94. PubMed
12. Dollery C. Pinacidil Monohydrate (monograph). In: Therapeutic Drugs. New York, NY: Churchill Livingstone; 1991:115-118.
13. Aqil M, Ali A. Monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: in-vitro characterization. Eur J Pharm Biopharm. 2002;54:161-164. PubMed DOI: 10.1016/S0939-6411(02)00059-0
14. Krakoff LR, Selvadurai R, Sytter E. Effect of methylprednisolone upon arterial pressure and the renin angiotensin system in the rat. Am J Physiol. 1975;228:613-617. PubMed
15. Plotz C, Knowlton A, Ragan C. The nature and history of Cushing's syndrome. Am J Med. 1952;13:597-611. PubMed DOI: 10.1016/ 0002-9343(52)90027-2
16. Soffer LJ, Iannaccone A, Gabrilove JL. Cushing's syndrome: a study of 50 patients. Am J Med 1961;30:129-134. DOI: 10.1016/0002-9343(61)90069-9
17. David DS, Grieco MH, Cushman P Jr. Adrenal glucocorticoids after 20 years: a review of their clinically relevant consequences. J Chronic Dis. 1970;22:637-648. PubMed DOI: 10.1016/0021-9681(70)90078-0
18. Ragan C. Corticotrophin. cortisone and related steroids in clinical medicine practical considerations. Bull-N. Acad Med. 1973;29:355-364.
19. Kotiyan PN, Vavia PR. Eudragits: role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol. Eur J Pharm Biopharm. 2001;52:173-180. PubMed DOI: 10.1016/S0939-6411(01)00174-6
20. Rao PR, Reddy MN, Ramakrishna S, Diwan PV. Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits. Eur J Pharm Biopharm. 2003;56:81-85. PubMed DOI: 10.1016/S0939-6411(03)00038-9
21. Guyot M, Fawaz F. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol. Int J Pharm. 2000;204:171-182. PubMed DOI: 10.1016/S0378-5173(00)00494-4
22. Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulasion for topical delivery of triptolide. Eur J Pharm Biopharm. 2003;56:189-196. PubMed DOI: 10.1016/S0939-6411(03)00067-5
23. Yoneto K, Ghanem AH, Higuchi WI, Peck KD, Li SK Mechanistic studies of the 1-alkyl-2-pyrrolidones as skin permeation enhancers, J Pharm Sci, 1995;84:312-317. PubMed
24. Yoneto K, Li SK, Higuchi WI, Shimabayashi S. Influence of the permeation enhancers 1-alkyl-2-pyrrolidones on permeant partitioning into the stratum corneum. J Pharm Sci. 1998;87:209-214. DOI: 10.1021/js970190k